Benzinga's Top Pre-Market NASDAQ Gainers (CLDA, GXDX, NVDA, ATPG)

Clinical Data Inc CLDA rose 43.25% to $21.53 in the pre-market session. The Food and Drug Administration (FDA) approved the CLDA's depression drug Viibryd. Genoptix Inc GXDX added 25.81% to $24.86 in the pre-market session. Novartis AG NVS announced its plans to acquire GXDX for $470 million, or $25 per share, representing a 39% premium over GXDX's share value on December 13, 2010. NVIDIA Corporation NVDA moved up 3.97% to $23.10 in the pre-market session. NVDA's trailing-twelve-month revenue is $3.64 billion. ATP Oil & Gas Corporation ATPG soared 2.81% to $16.08 in the pre-market trading. ATPG shares have dropped 3.69% over the past 52 weeks, while the S&P 500 index has gained 17.55% in the same period. Read more from Benzinga's Markets.